Expanding Veterans’ Access to Emerging Treatments Act
HB7091, the Expanding Veterans’ Access to Emerging Treatments Act, would direct the Department of Veterans Affairs to create an investigational research and extended-access treatment program for veterans with certain unmet medical needs. The bill focuses on conditions such as chronic pain, PTSD, depression, anxiety, substance use disorders, and traumatic brain injury, and it specifically contemplates the use of innovative treatments and emerging therapies, including psychedelic-assisted and other novel interventions. It also states Congress’s view that the VA should advance research and timely access to these therapies for veterans who have not responded to existing options.
Under the bill, the VA would have to establish the program within 90 days of enactment and designate a lead administrator within 60 days. The department could run clinical trials, develop compassionate-use or extended-access protocols, and consider veterans for participation or access when clinically appropriate. The bill also requires a report to Congress within one year on participating clinics, expected enrollment, trial outcomes, and the safety, efficacy, cost, regulatory, and logistical issues associated with the therapies used. The program would be reviewed after two years and could be extended or terminated by the Secretary of Veterans Affairs.
The bill would add a new VA research and access framework for investigational treatments aimed at veterans with specified covered conditions, while expressly preserving compliance with federal law governing investigational medical products and controlled substances. It would not itself legalize any substance or therapy, but it would authorize the VA to organize clinical trials and compassionate or extended access pathways for treatments such as psilocybin, MDMA, ketamine, ibogaine, and certain emerging devices or pharmaceutical candidates. The measure would primarily affect the Department of Veterans Affairs, veterans seeking treatment for qualifying conditions, and clinics or researchers participating in the program.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears supportive and reform-oriented. The bill’s findings frame the issue as an urgent unmet medical need for veterans and present the program as a way to expand treatment options where existing care has been insufficient. The bipartisan sponsorship by Representatives Bergman and Correa also suggests cross-party interest in exploring new therapies for veterans.
The main point of contention is likely to be the use of psychedelic and other investigational therapies, especially because the bill references substances and treatments that remain tightly regulated under federal law. Supporters are likely to emphasize unmet need, clinical research, and expanded access for veterans with treatment-resistant conditions, while critics may raise concerns about safety, efficacy, regulatory compliance, and the appropriateness of VA involvement in therapies that are still experimental. The bill tries to address those concerns by limiting the program to lawful investigational use and requiring reporting on safety, cost, and logistical considerations.